0A6R Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Clinical Trial Progression (Cohort Advancement)DSMB clearance for Cohort 2 and initiation of Cohort 3 materially de-risks the program on safety and shows the company can execute multicohort clinical work. Durable operational progress increases likelihood of subsequent trials and regulatory engagement, strengthening development credibility long-term.
Expense Discipline And Reduced Operating CostsSustained, sizable year-over-year expense reductions reflect active management of the cost base and improve structural burn dynamics. Lower fixed spending enhances runway flexibility, reduces dependence on urgent financing, and indicates stronger stewardship of capital—important for development-stage firms.
Device Compatibility With Simplified Blood PumpCompatibility with a simplified pump reduces infrastructure requirements and broadens potential treatment sites. This structural enabler can lower adoption friction, expand the addressable market beyond dialysis units, and improve commercial feasibility if clinical efficacy is demonstrated.
Bears Say
Constrained Liquidity Relative To Operating LossesReported cash balances plus recent ATM proceeds appear insufficient to cover a full year of current operating losses, forcing reliance on incremental financings. This structural funding gap raises execution risk for clinical programs, increases dilution potential, and can constrain long-term strategy and trial pacing.
Persistent Operating Losses And Minimal RevenueOngoing multi-year losses with little-to-no recurring revenue erode shareholder equity and prevent internal funding of R&D. This structural lack of self-generated cash makes the business perpetually financing-dependent and heightens risk that development timelines and commercialization plans will be delayed without new capital.
Small, Non‑powered Study And Enrollment UncertaintyRelying on a small safety-focused trial limits near-term ability to demonstrate efficacy or obtain regulatory approvals. Enrollment attrition and small cohorts can delay definitive outcomes, require larger follow‑on trials, and materially extend the timeline and capital needed for commercialization—structural program risk.
Aethlon Medical News
0A6R FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Currently, no data Available
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is €1.71M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Nov 18, 2026 which is in 96 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Aug 13, 2026. The company reported -€3.485 earnings per share for the quarter, missing the consensus estimate of -€3.403 by -€0.082.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Undervalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -3.34.
How many shares outstanding does Aethlon Medical Inc have?
Currently, no data Available
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of -€3.485 in its last earnings report, missing expectations of -€3.403. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in GB:0A6R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
0A6R Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced tangible near-term progress with clear caveats. Positives include advancement into the final clinical cohort, encouraging Cohort 2 biomarker signals, a peer-reviewed Long COVID preclinical publication, ongoing R&D expansion, an improved post-quarter cash position following a ~$4.0M financing, and an 11.9% reduction in operating expenses. Key negatives are that clinical observations are preliminary and based on very small sample sizes, statistical analyses are pending, dosing is logistically constrained, and larger trials will require additional capital or partnerships. Overall, the company shows disciplined resource management and meaningful early scientific signals but faces validation, scale and funding headwinds before efficacy or regulatory clarity can be established.View all GB:0A6R earnings summaries